Rieke Alten

15.3k total citations · 4 hit papers
221 papers, 9.6k citations indexed

About

Rieke Alten is a scholar working on Rheumatology, Hematology and Immunology. According to data from OpenAlex, Rieke Alten has authored 221 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 163 papers in Rheumatology, 62 papers in Hematology and 62 papers in Immunology. Recurrent topics in Rieke Alten's work include Rheumatoid Arthritis Research and Therapies (137 papers), Autoimmune and Inflammatory Disorders Research (55 papers) and Chronic Lymphocytic Leukemia Research (45 papers). Rieke Alten is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (137 papers), Autoimmune and Inflammatory Disorders Research (55 papers) and Chronic Lymphocytic Leukemia Research (45 papers). Rieke Alten collaborates with scholars based in Germany, United States and United Kingdom. Rieke Alten's co-authors include Thasia Woodworth, Joachim Sieper, André Beaulieu, Joachim Listing, Andrea Rubbert‐Roth, César Ramos-Remus, Josef S Smolen, Emma Alecock, J Rovenský and Paul Emery and has published in prestigious journals such as New England Journal of Medicine, The Lancet and PLoS ONE.

In The Last Decade

Rieke Alten

210 papers receiving 9.2k citations

Hit Papers

Effect of interleukin-6 receptor inhibition with tocilizu... 2002 2026 2010 2018 2008 2002 2003 2013 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
    2008 1.1k citations Andrea Rubbert‐Roth, Thasia Woodworth et al. profile →
  2. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial
    2002 953 citations Rieke Alten et al. profile →
  3. Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig
    2003 807 citations René Westhovens, Rieke Alten et al. profile →
  4. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
    2013 502 citations Rieke Alten, Arthur Kavanaugh et al. profile →

Peers

Rieke Alten
Alain Cantagrel France
Arthur Kavanaugh United States
Axel Finckh Switzerland
Christian Antoni Germany
F. C. Breedveld Netherlands
Thasia Woodworth United States
Alexandre E. Voskuyl Netherlands
Alan Kivitz United States
Daniel Wendling France
Jaap Fransen Netherlands
Alain Cantagrel France
Rieke Alten
Citations per year, relative to Rieke Alten Rieke Alten (= 1×) peers Alain Cantagrel

Countries citing papers authored by Rieke Alten

Since Specialization
Citations

This map shows the geographic impact of Rieke Alten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rieke Alten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rieke Alten more than expected).

Fields of papers citing papers by Rieke Alten

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rieke Alten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rieke Alten. The network helps show where Rieke Alten may publish in the future.

Co-authorship network of co-authors of Rieke Alten

This figure shows the co-authorship network connecting the top 25 collaborators of Rieke Alten. A scholar is included among the top collaborators of Rieke Alten based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rieke Alten. Rieke Alten is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Taylor, Peter C., Ewa Haładyj, Inmaculada de la Torre, et al.. (2024). Association Between Patient-Reported Pain and Remission or Low Disease Activity in Patients with Rheumatoid Arthritis: Data from RA-BE-REAL Prospective Observational Study. Rheumatology and Therapy. 12(1). 109–122. 1 indexed citations
2.
Alten, Rieke, Juan Carlos Nieto‐González, Peggy Jacques, et al.. (2024). What benefit–risk trade-offs are acceptable to rheumatoid arthritis patients during treatment selection? Evidence from a multicountry choice experiment. RMD Open. 10(1). e003311–e003311.
3.
Taylor, Peter C., Arthur Kavanaugh, Peter Nash, et al.. (2024). Impact of filgotinib on pain control in the phase 3 FINCH studies. RMD Open. 10(1). e003839–e003839. 5 indexed citations
4.
5.
6.
Taylor, Peter C., Arthur Kavanaugh, Peter Nash, et al.. (2023). AB0290 EFFECT OF FILGOTINIB ON PAIN IN PATIENTS WITH RHEUMATOID ARTHRITIS IN THE PHASE 3 FINCH 1, 2 AND 3 STUDIES. Lirias (KU Leuven). 1326.2–1327. 1 indexed citations
7.
Foldenauer, Ann Christina, Rieke Alten, Martin Aringer, et al.. (2022). Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA). Journal of Clinical Medicine. 11(24). 7316–7316. 1 indexed citations
8.
Alten, Rieke, et al.. (2022). Re-Routing Infliximab Therapy: Subcutaneous Infliximab Opens a Path Towards Greater Convenience and Clinical Benefit. Clinical Drug Investigation. 42(6). 477–489. 13 indexed citations
9.
Alten, Rieke, Xavier Mariette, René‐Marc Flipo, et al.. (2021). OP0180 IMPACT OF RF AND ANTI-CITRULLINATED PROTEIN ANTIBODY SEROSTATUS ON 2-YEAR RETENTION OF ABATACEPT IN PATIENTS WITH RA. Annals of the Rheumatic Diseases. 80. 108–108.
10.
Alten, Rieke, et al.. (2020). Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases. 23(11). 1514–1525. 10 indexed citations
11.
Kim, HoUng, Rieke Alten, Luisa Avedano, et al.. (2020). The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases. Drugs. 80(2). 99–113. 73 indexed citations
12.
13.
Gulàcsi, László, Zsombor Zrubka, Valentin Brodszky, et al.. (2019). Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis. Advances in Therapy. 36(3). 721–745. 7 indexed citations
14.
Zrubka, Zsombor, László Gulàcsi, Valentin Brodszky, et al.. (2019). Long-term efficacy and cost-effectiveness of infliximab as first-line treatment in rheumatoid arthritis: systematic review and meta-analysis. Expert Review of Pharmacoeconomics & Outcomes Research. 19(5). 537–549. 18 indexed citations
15.
Pickles, Timothy, Rieke Alten, Maarten Boers, et al.. (2019). Adaptive Trial Designs in Rheumatology: Report from the OMERACT Special Interest Group. The Journal of Rheumatology. 46(10). 1406–1408. 8 indexed citations
16.
Taylor, Peter C., Rieke Alten, Juan J. Gómez‐Reino, et al.. (2018). Factors influencing use of biologic therapy and adoption of treat-to-target recommendations in current European rheumatology practice. Patient Preference and Adherence. Volume 12. 2007–2014. 6 indexed citations
17.
Kiltz, Uta, Rieke Alten, Marcelo P. Fleck, et al.. (2016). [Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)].. PubMed. 75 Suppl 2. 11–60. 17 indexed citations
18.
19.
Alten, Rieke, Jeffrey Kaine, Edward Keystone, et al.. (2012). Safety profile of subcutaneous abatacept focusing On clinically relevant events in patients with rheumatoid arthritis and up to 4.5 years of exposure. Queensland's institutional digital repository (The University of Queensland). 3 indexed citations
20.
Bingham, Clifton O., Christoph Pohl, Rieke Alten, et al.. (2009). “Flare” and disease worsening in rheumatoid arthritis: Time for a definition. UWE Research Repository (UWE Bristol). 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Alain Cantagrel Breakdown of academic impact, for papers by Arthur Kavanaugh Breakdown of academic impact, for papers by Axel Finckh Breakdown of academic impact, for papers by Christian Antoni Breakdown of academic impact, for papers by F. C. Breedveld Breakdown of academic impact, for papers by Thasia Woodworth Breakdown of academic impact, for papers by Alexandre E. Voskuyl Breakdown of academic impact, for papers by Alan Kivitz Breakdown of academic impact, for papers by Daniel Wendling Breakdown of academic impact, for papers by Jaap Fransen
Rankless by CCL
2026